Key Highlights
- Inhibrx Biosciences (NASDAQ: INBX) expands its credit facility to $500 million, drawing $100 million upfront.
- Company gains option to access an additional $225 million in $50 million increments at lender discretion.
- Warrants issued for 21,457 shares at $93.21 per share, with a long‑term exercise window.
- Facility includes pledge of equity in Poplar Therapeutics as collateral.
Inhibrx Biosciences has secured a credit facility with a total commitment of $500 million and has drawn $100 million to support its clinical development programs. The agreement with Oxford Finance provides the company with the ability to draw an additional $225 million in $50 million blocks, giving flexibility as it moves forward with its pipeline.
Facility Expanded to $500 Million
The recent amendment increases the total borrowing capacity to $500 million. The structure now contains a $100 million term loan funded at the closing of the amendment and a supplemental tranche that may be drawn in $50 million increments up to $225 million. The prior arrangement had already funded a portion of the facility, and the new tranche serves as a strategic reserve for future needs.
This expanded capacity is intended to fund continued work on lead programs such as INBRX‑109 and INBRX‑106.
Mechanics of the New Tranche
The expansion separates the facility into two components: an immediate $100 million draw and an optional $225 million tranche. Lenders retain discretion over any additional drawdowns, which must be requested in multiples of $50 million. Future draws under the supplemental tranche will trigger additional warrants calculated on a similar basis, with the exercise price tied to a market‑based reference.
The warrants are exercisable over an extended period, adding an equity component to the overall debt package. Collateral for the facility now includes a pledge of Inhibrx’s equity interest in Poplar Therapeutics, broadening the security beyond its clinical assets.
Why the Move Matters Now
The $100 million draw delivers immediate liquidity, extending the company’s cash runway and reducing short‑term financing risk ahead of key clinical milestones. The optional $225 million tranche offers a non‑dilutive source of capital that can be accessed if additional resources are required for trial extensions, regulatory engagements, or accelerated development. The structure reflects lender confidence in the company’s pipeline while providing a disciplined financing framework that avoids the need for an immediate public equity offering.
Next Catalyst: Clinical Data Readouts
Inhibrx’s near‑term focus remains on generating data from its lead programs, including INBRX‑109 and INBRX‑106. The secured $100 million ensures that the company can fund operations through upcoming readouts, while the optional $225 million tranche serves as a contingency to support further development activities if needed. Stakeholders will monitor announcements regarding the timing of these readouts and any subsequent draw requests under the supplemental tranche, which together will shape the company’s path toward commercial realization.
Based on the recent Form 8‑K filing.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.




_11_17_2026_20_37_58_946960.jpg)

Please wait processing your request...